Welcome to CrownBio’s Oncology Blog where we share our thoughts
on the latest trends and hot stories in Oncology


Using T Cells in Immuno-Oncology

by John MacDougall PhD, March 1, 2018 at 01:00 PM | Tags

t cell activation, diversity, helper, memory, suppressor, cytotoxic, MHC antigen complex, antigen presentation

t cell activation presentation maturation diversification chart crown bioImmuno-oncology drug development challenges researchers to model the interaction between novel immunotherapy agents, functional T cells, and in vivo models of cancer. In this introduction to T cells and immunotherapy studies, we’ll explore the function and analysis of T cells in preclinical drug development.

What Are T Cells?

T cells belong to the subset of leukocytes responsible for cell mediated immunity. Their main function is to fight viruses by killing virally infected cells, thereby stopping virus replication. This is achieved through a complex network of proteins expressed on both the T cell and the target cell.

These proteins coordinate both the recognition of the infected target cell by the T cell, and the subsequent activation of the T cell:

  • Recognition is achieved through the target cell presenting viral peptides, which T cells distinguish as foreign.

  • Activation is achieved through stimulation of a complex network of cell surface and soluble ligands, and cell surface receptor signaling molecules.

T Cell Subsets and Functions

There are subtypes of T cells, too, defined by cellular function and cell surface markers.

There are other T cell subtypes, as well, and each contributes to the coordinating and carrying out an effective, cell-mediated immune response.

Cancers Hijack Regulatory Systems to Suppress T Cells

From the above description, T cells seem to be the perfect host defense against cancer. T cells generate a coordinated effective cytotoxic response, and they remember. Yet, cancer still happens. We now know that cancers leverage a number of regulatory systems designed to diminish an immune response – and this has given rise to the currently approved immuno-oncology agents targeting the so-called checkpoint pathways (e.g. antibodies against PD-1, PD-L1 and CTLA-4).

Understanding how novel experimental therapies augment T cell function is critical to progress in cancer immunotherapy. This is where many preclinical challenges still reside. Syngeneic animal models of cancer, models in which there is a complete immune system, have been used widely to illuminate different mechanisms of cancer immunotherapy.

Preclinical Immunotherapy Models

How do we best use these models? Our goal is to kill cancer cells, and this typically translates to %TGI endpoints in animal studies. Making tumors smaller is always a good goal, and eliminating them is ideal, but understanding how this is achieved is another matter. Making immunologically “cold” tumors “hot” is also a critical goal.

Analyzing whether enhanced cancer cell killing is related to T cell activation, proliferation, or migration, and what T cell subset is being affected by an experimental therapy, will help us better evaluate candidates for combination therapy. For instance, combining two agents, one that enhances T cell migration and one that enhances T cell killing would be desirable.

Monitoring Immunotherapy PD Endpoints and T Cell Spectrum with Flow Cytometry

For immunotherapy studies, these pharmacodynamic endpoints are typically measured through flow cytometry. Multicolor staining and gating approaches allows researchers to profile many different cell types in a tumor sample, including a complete spectrum of T cells.

Cellular activation can be measured through the assessment of cytokine production, and cell proliferation can be measured through markers expressed in dividing cells. For a comprehensive assessment of cell populations within a tumor mass, flow cytometry cannot be beaten.

Maintaining Spatial Information with Immunohistochemistry

There is one drawback to flow cytometry, however. To facilitate the analysis, the tissue sample must be processed into a single cell suspension. This processing destroys any spatial information about the cells within the sample. Therefore, one might not be able to distinguish between “hot” tumors and “cold” tumors, where the immune cells are present but have been excluded.

how t cells migrate into inflamed excluded and ignored tumors

In this case, it is always a good idea to have access to histological samples to make any assessments of the spatial distribution of cells within a tumor. While not as high throughput, immunohistochemical approaches can highlight all of the same markers used in flow cytometry, with the advantage of maintaining spatial orientation of the various cell populations in the tumor.

Understand the Immune System to Enhance Immunotherapy

Immunotherapies are indirect approaches to cancer treatment; the drugs augment the function of immune cells, which then affect the cancer. With this in mind, it becomes critical to go beyond %TGI to better understand how to harness the immune system in cancer immunotherapy.


Related posts

Tumor Heterogeneity in Preclinical Oncology Models

Real tumors are complex and heterogeneous, which has long frustrated efforts to recapitulate the disease in a controlled setting. What causes tumor...

Preclinical Imaging of Non-Solid Tumors

Learn how preclinical imaging helps overcome the particular challenges associated with modeling leukemia and other non-solid tumors.

RAS: Targeting the Impossible

Explore the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming...